

I. **AMENDMENTS TO THE CLAIMS:**

1-10. (Canceled)

11. (Currently Amended) A method of treating psoriasis affected area of the skin, scalp or nails comprising the steps of:

- a) [[Orally]] orally administering to [[the]] a psoriasis affected individual a composition comprising boswellic acid and a selenium compound and, ~~and dispersed in~~ a pharmaceutically acceptable carrier; and
- b) topically applying to the [[said]] affected area a composition of boswellic acid and ~~dispersed in~~ a pharmaceutically acceptable carrier.

12. (Currently Amended) The method of treating psoriasis affected area of the skin, scalp or nails, ~~as defined in Claim claim~~ 11, wherein the orally administered composition contains about 400 mg of boswellic acid represented by one or more of the following groups:

- a) beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as single entities or mixtures; and
- b) ~~Congeners~~ congeners or derivatives of beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as single entities or mixtures.

13. (Currently Amended) The method of ~~treating psoriasis affected area of the skin, scalp or nails, as defined in Claim~~ claim 11, wherein the orally administered composition contains about 100 micrograms of selenium derived from one or more of the following selenium sources: selenomethionine, Selmethylselenocystein, derivatives of selenomethionine, derivatives of Semethylselenocystein, and high selenium yeast.

14. (Currently Amended) The method of ~~treating psoriasis affected area of the skin, scalp or nails, as defined in Claim~~ claim 11, wherein the topically administered composition contains about 400 mg of boswellic acid represented by one or more of the following groups:

- a) beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as a single entities or mixtures; and
- b) ~~Congeners~~ congeners or derivatives of beta-boswellic acid, acetyl beta-boswellic acid, 11-keto beta-boswellic acid, acetyl-11-keto-beta-boswellic acid, as single entities or mixtures.

15. (Currently Amended) The method of ~~treating psoriasis affected area of the skin, scalp or nails, as defined in Claim~~ claim 11, wherein the orally administered composition contains about 400 mg of acetyl-11-keto-beta-boswellic acid.

16. (Currently Amended) The method of ~~treating psoriasis affected area of the skin, scalp or nails, as defined in Claim~~ claim 11, wherein the orally administered composition

contains about 100 micrograms of selenium from L(+)-Selenomethionine, in a pharmaceutically acceptable carrier.

17. (Currently Amended) The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim claim 11, wherein the topically administered composition contains about 400 mg of acetyl-11-keto-beta-boswellic acid dispersed in a pharmaceutically acceptable carrier.
18. (Currently Amended) The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim claim 11, wherein the total daily oral dose of boswellic acid is about 1200 mg, administered in a plurality of individual doses.
19. (Currently Amended) The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim claim 11, wherein the total daily oral dose of selenium is about 300 micrograms, administered in a plurality of individual doses.
20. (Currently Amended) The method of treating psoriasis affected area of the skin, scalp or nails, as defined in Claim claim 11, wherein the total daily topical dose of boswellic acid is about 1200 mg, administered in a plurality of individual doses.